Logo image of 5CV.DE

CUREVAC NV (5CV.DE) Stock Price, Quote, News and Overview

FRA:5CV - Deutsche Boerse Ag - NL0015436031 - Common Stock - Currency: EUR

2.86  -0.07 (-2.52%)

5CV.DE Quote, Performance and Key Statistics

CUREVAC NV

FRA:5CV (3/7/2025, 7:00:00 PM)

2.86

-0.07 (-2.52%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.81
52 Week Low2.11
Market Cap641.61M
Shares224.34M
Float122.80M
Yearly DividendN/A
Dividend YieldN/A
PE5.96
Fwd PEN/A
Earnings (Next)04-22 2025-04-22/amc
IPO08-14 2020-08-14


5CV.DE short term performance overview.The bars show the price performance of 5CV.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

5CV.DE long term performance overview.The bars show the price performance of 5CV.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of 5CV.DE is 2.86 EUR. In the past month the price decreased by -18.8%. In the past year, price decreased by -7.44%.

CUREVAC NV / 5CV Daily stock chart

5CV.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About 5CV.DE

Company Profile

5CV logo image CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 999 full-time employees. The company went IPO on 2020-08-14. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Company Info

CUREVAC NV

Friedrich-Miescher-Str. 15

Tuebingen BADEN-WUERTTEMBERG DE

Employees: 1086

Company Website: https://www.curevac.com/

Investor Relations: https://www.curevac.com/en/investor-relations/

Phone: 49707198830

CUREVAC NV / 5CV.DE FAQ

What is the stock price of CUREVAC NV today?

The current stock price of 5CV.DE is 2.86 EUR. The price decreased by -2.52% in the last trading session.


What is the ticker symbol for CUREVAC NV stock?

The exchange symbol of CUREVAC NV is 5CV and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is 5CV.DE stock listed?

5CV.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for CUREVAC NV stock?

13 analysts have analysed 5CV.DE and the average price target is 7.48 EUR. This implies a price increase of 161.46% is expected in the next year compared to the current price of 2.86. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CUREVAC NV worth?

CUREVAC NV (5CV.DE) has a market capitalization of 641.61M EUR. This makes 5CV.DE a Small Cap stock.


How many employees does CUREVAC NV have?

CUREVAC NV (5CV.DE) currently has 1086 employees.


What are the support and resistance levels for CUREVAC NV (5CV.DE) stock?

CUREVAC NV (5CV.DE) has a support level at 2.85 and a resistance level at 3.61. Check the full technical report for a detailed analysis of 5CV.DE support and resistance levels.


Is CUREVAC NV (5CV.DE) expected to grow?

The Revenue of CUREVAC NV (5CV.DE) is expected to grow by 700.96% in the next year. Check the estimates tab for more information on the 5CV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CUREVAC NV (5CV.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CUREVAC NV (5CV.DE) stock pay dividends?

5CV.DE does not pay a dividend.


When does CUREVAC NV (5CV.DE) report earnings?

CUREVAC NV (5CV.DE) will report earnings on 2025-04-22, after the market close.


What is the Price/Earnings (PE) ratio of CUREVAC NV (5CV.DE)?

The PE ratio for CUREVAC NV (5CV.DE) is 5.96. This is based on the reported non-GAAP earnings per share of 0.48 and the current share price of 2.86 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 5CV.DE.


5CV.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is a bad performer in the overall market: 82.1% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

5CV.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE. While 5CV.DE has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

5CV.DE Financial Highlights

Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of 0.48. The EPS increased by 134.53% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.93%
ROA 12.68%
ROE 14.94%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%781.82%
Sales Q2Q%2896.43%
EPS 1Y (TTM)134.53%
Revenue 1Y (TTM)1166.88%

5CV.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to 5CV.DE. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 164.54% and a revenue growth 700.96% for 5CV.DE


Ownership
Inst Owners18.11%
Ins Owners0.18%
Short Float %N/A
Short RatioN/A
Analysts
Analysts78.46
Price Target7.48 (161.54%)
EPS Next Y164.54%
Revenue Next Year700.96%